Australia markets closed

BioPorto A/S (THOXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.75000.0000 (0.00%)
At close: 09:36AM EDT

BioPorto A/S

Tuborg Havnevej 15
Ground Floor
Hellerup 2900
45 45 29 00 00

Sector(s):Β Healthcare
Industry:Β Diagnostics & Research
Full-time employees:Β 29

Key executives

NameTitlePayExercisedYear born
Mr. Anthony P. PareChief Exec. OfficerN/AN/A1963
Mr. Neil A. Goldman CPAExec. VP & CFON/AN/A1968
Lars Otto UttenthalChief Scientific OfficerN/AN/AN/A
Ms. Gry Husby LarsenGen. CounselN/AN/AN/A
Dr. Christopher BirdChief Medical Officer506.84kN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.

Corporate governance

BioPorto A/S’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.